Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 551 to 575 of 1139 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
551 increased cholecystokinin (PR:000005110) 1061: prolonged, elevation of serun CCK
552 increased cell proliferation (GO:0008283) acinar cell (CL:0000622) 1062: Increased, Cellular proliferation / hyperplasia of acinar cells
553 increased intracellular estrogen receptor signaling pathway (GO:0030520) estrogen receptor alpha complex (PR:000027727) 1065: Activation, estrogen receptor alpha
554 increased gene expression (GO:0010467) homeobox protein SIX1 (PR:000014896) 2329: Sine oculis homeobox 1 gene expression, increased
555 increased cell proliferation (GO:0008283) basal cell (CL:0000646) 1067: Proliferation/Clonal Expansion, aberrant basal-type cells
556 morphological change Metaplasia (MESH:D008679) None
557 increased hyperplasia (MESH:D006965) glandular epithelial cell (CL:0000150)
558 increased adenosquamous carcinoma (MESH:D018196) 1070: Increased, adenosquamous carcinomas of endometrium
559 disrupted abnormal ovulation (MP:0001928) 1074: interruption, Ovulation
560 delayed estrus (GO:0060209) None
561 increased estrogen (CHEBI:50114) 1076: Increased, circulating estrogen levels
562 increased prolactin (PR:000013246) 1077: Increased, prolactin exposure
563 increased mammary gland hyperplasia (MP:0000630) 1078: Hyperplasia, Mammary gland
564 increased abnormal tumor latency (MP:0010307) 1080: Increased, latency period
565 increased hyperplasia (MESH:D006965) prolactin secreting cell (CL:0000439) 1081: Increased, lactotroph hyperplasia and hypertrophy
566 increased hypertrophy (MESH:D006984) prolactin secreting cell (CL:0000439) 1081: Increased, lactotroph hyperplasia and hypertrophy
567 increased Pituitary adenoma (HP:0002893) Adenoma (MESH:D000236) 1082: Increased, adenomas (pituitary)
568 increased synaptic transmission, dopaminergic (GO:0001963) dopaminergic neuron (CL:0000700) 1083: Decreased, Dopaminergic activity
569 increased prolactin secretion (GO:0070459) prolactin (PR:000013246) 1084: Increased, prolactin secretion
570 increased hyperplasia (MESH:D006965) mammary gland (UBERON:0001911) 1085: Increased, hyperplasia (mammary gland)
571 increased cell death (GO:0008219) pleura (UBERON:0000977) 1086: persistent, cytotoxicity (pleura or peritoneum)
572 increased cell proliferation (GO:0008283) mesothelium (UBERON:0001136) 1089: Increased, Cell Proliferation (mesothelium)
573 increased mesothelioma (MESH:D008654) None
574 increased metamorphosis (GO:0007552) 1101: Altered, Amphibian metamorphosis
575 increased 3,3',5-triiodo-L-thyronine (CHEBI:18258) 1116: Decreased, Triiodothyronine (T3) in tissues